CO6531498A2 - COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS - Google Patents
COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOSInfo
- Publication number
- CO6531498A2 CO6531498A2 CO12069732A CO12069732A CO6531498A2 CO 6531498 A2 CO6531498 A2 CO 6531498A2 CO 12069732 A CO12069732 A CO 12069732A CO 12069732 A CO12069732 A CO 12069732A CO 6531498 A2 CO6531498 A2 CO 6531498A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- raf
- treatment
- useful
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una combinación novedosa que comprende el inhibidor de MEK de N-{3-[3-cicIopropiI-5-(2-fluoro-4-yodo-feniI-amino)-6,8-dimetiI-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido-[4,3-d]-pirimidin-1-il]-fenil}-acetamida, o una sal farmacéuticamente aceptable o un solvato de la misma, con un inhibidor de B-Raf, en particular N-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetil-etil)-1,3-tiazol-4-iI]-2-fluoro-fenil)-2,6-difluoro-bencen-sulfonamida o una sal farmacéuticamente aceptable de la misma, composiciones farmacéuticas que la comprenden, y métodos para utilizar estas combinaciones y composiciones en el tratamiento de las condiciones en donde sea benéfica la inhibición de MEK y/o B-Raf, por ejemplo, cáncer.Sector: Composiciones químicas capaces de inhibir MEK y B-Raf, siendo útiles para el tratamiento del cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25221309P | 2009-10-16 | 2009-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6531498A2 true CO6531498A2 (es) | 2012-09-28 |
Family
ID=43876568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12069732A CO6531498A2 (es) | 2009-10-16 | 2012-04-27 | COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8703781B2 (es) |
| EP (4) | EP4397376A2 (es) |
| JP (1) | JP5718929B2 (es) |
| KR (1) | KR101729116B1 (es) |
| CN (1) | CN102655753B (es) |
| AU (1) | AU2010306653B2 (es) |
| BR (1) | BR112012008854B8 (es) |
| CA (1) | CA2775803C (es) |
| CL (1) | CL2012000964A1 (es) |
| CO (1) | CO6531498A2 (es) |
| CR (1) | CR20120155A (es) |
| CY (1) | CY1122013T1 (es) |
| DK (2) | DK3560498T3 (es) |
| DO (1) | DOP2012000091A (es) |
| EA (1) | EA020589B1 (es) |
| ES (2) | ES2930157T3 (es) |
| HR (2) | HRP20221304T1 (es) |
| HU (2) | HUE060206T2 (es) |
| IL (1) | IL219073A (es) |
| LT (2) | LT3560498T (es) |
| MA (1) | MA33746B1 (es) |
| ME (1) | ME03497B (es) |
| MX (1) | MX2012004413A (es) |
| MY (1) | MY174759A (es) |
| NZ (1) | NZ598913A (es) |
| PE (1) | PE20121093A1 (es) |
| PL (2) | PL2488033T3 (es) |
| PT (2) | PT3560498T (es) |
| RS (2) | RS63702B1 (es) |
| SI (1) | SI2488033T1 (es) |
| UA (1) | UA105064C2 (es) |
| WO (1) | WO2011047238A1 (es) |
| ZA (1) | ZA201202612B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903981T4 (tr) | 2008-06-16 | 2019-04-22 | Univ Ohio State Res Found | Kanser tedavisi için bileşikler. |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
| EP2635286A4 (en) * | 2010-11-05 | 2014-11-12 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR THE TREATMENT OF CANCER |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US9580501B2 (en) | 2011-12-16 | 2017-02-28 | Synthon Biopharmaceuticals B.V. | Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases |
| AU2012358999A1 (en) * | 2011-12-22 | 2014-07-10 | Glaxosmithkline Llc | Method of treating cancer with MAGEA3 immunotherapeutic with BRAF inhibitor and/or MEK inhibitor |
| CA2868954A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| DK2892535T3 (da) | 2012-09-04 | 2022-01-03 | Novartis Ag | Fremgangsmåde til adjuverende cancerbehandling |
| WO2014066606A2 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Llc | Combination |
| ES2686730T3 (es) | 2012-11-30 | 2018-10-19 | Novartis Ag | Composición farmacéutica novedosa |
| CN103965170A (zh) * | 2013-01-24 | 2014-08-06 | 通化济达医药有限公司 | 苯磺酰胺吡唑激酶抑制剂 |
| CN109568312A (zh) | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| US10010608B2 (en) * | 2013-05-31 | 2018-07-03 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US20160089434A1 (en) * | 2013-06-03 | 2016-03-31 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| WO2015003571A1 (zh) * | 2013-07-08 | 2015-01-15 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的新晶型及其制备方法 |
| WO2015059677A1 (en) * | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| CN103588767B (zh) * | 2013-11-20 | 2016-01-20 | 苏州明锐医药科技有限公司 | 达拉菲尼的制备方法 |
| AU2014362995A1 (en) * | 2013-12-12 | 2016-05-26 | Novartis Ag | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| WO2015100427A1 (en) | 2013-12-28 | 2015-07-02 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| WO2015105822A1 (en) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Cancer treatment method |
| ES2815374T3 (es) | 2014-05-06 | 2021-03-29 | Oncternal Therapeutics Inc | Compuestos para el tratamiento del cáncer |
| KR101629184B1 (ko) | 2014-12-10 | 2016-06-13 | 현대오트론 주식회사 | Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법 |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| AU2017354019A1 (en) * | 2016-11-03 | 2019-05-23 | The Regents Of The University Of Michigan | Small molecule dual inhibitors of EGFR/PI3K and uses thereof |
| US20210348238A1 (en) | 2018-10-16 | 2021-11-11 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020323033A1 (en) * | 2019-07-26 | 2021-04-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021118924A2 (en) | 2019-12-12 | 2021-06-17 | Ting Therapeutics Llc | Compositions and methods for the prevention and treatment of hearing loss |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
| CA3236424A1 (en) * | 2021-11-02 | 2023-05-11 | Verastem, Inc. | Methods of treating abnormal cell growth |
| WO2023105286A1 (en) | 2021-12-06 | 2023-06-15 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| TR200201364T2 (tr) * | 1999-11-22 | 2002-10-21 | Smithkline Beecham P. L. C. | Yeni bileşikler. |
| DE102004018198A1 (de) * | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| PL2298768T3 (pl) * | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
| WO2008120004A1 (en) * | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| JP5479337B2 (ja) | 2007-07-30 | 2014-04-23 | アルディア バイオサイエンス，インク． | Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用 |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
-
2010
- 2010-10-15 LT LTEP19174594.2T patent/LT3560498T/lt unknown
- 2010-10-15 HU HUE19174594A patent/HUE060206T2/hu unknown
- 2010-10-15 ES ES19174594T patent/ES2930157T3/es active Active
- 2010-10-15 US US13/499,779 patent/US8703781B2/en active Active
- 2010-10-15 PL PL10824148T patent/PL2488033T3/pl unknown
- 2010-10-15 JP JP2012534386A patent/JP5718929B2/ja active Active
- 2010-10-15 DK DK19174594.2T patent/DK3560498T3/da active
- 2010-10-15 AU AU2010306653A patent/AU2010306653B2/en active Active
- 2010-10-15 EP EP24175377.1A patent/EP4397376A2/en active Pending
- 2010-10-15 ES ES10824148T patent/ES2745479T3/es active Active
- 2010-10-15 KR KR1020127012649A patent/KR101729116B1/ko active IP Right Grant
- 2010-10-15 CN CN201080046640.6A patent/CN102655753B/zh active Active
- 2010-10-15 PE PE2012000502A patent/PE20121093A1/es active IP Right Grant
- 2010-10-15 SI SI201031933T patent/SI2488033T1/sl unknown
- 2010-10-15 BR BR112012008854A patent/BR112012008854B8/pt active IP Right Grant
- 2010-10-15 CA CA2775803A patent/CA2775803C/en active Active
- 2010-10-15 MY MYPI2012001680A patent/MY174759A/en unknown
- 2010-10-15 WO PCT/US2010/052808 patent/WO2011047238A1/en active Application Filing
- 2010-10-15 DK DK10824148.0T patent/DK2488033T3/da active
- 2010-10-15 PT PT191745942T patent/PT3560498T/pt unknown
- 2010-10-15 EP EP19174594.2A patent/EP3560498B1/en active Active
- 2010-10-15 HR HRP20221304TT patent/HRP20221304T1/hr unknown
- 2010-10-15 EP EP10824148.0A patent/EP2488033B1/en active Active
- 2010-10-15 UA UAA201204675A patent/UA105064C2/uk unknown
- 2010-10-15 MX MX2012004413A patent/MX2012004413A/es active IP Right Grant
- 2010-10-15 ME MEP-2019-236A patent/ME03497B/me unknown
- 2010-10-15 RS RS20220984A patent/RS63702B1/sr unknown
- 2010-10-15 RS RSP20191095 patent/RS59181B1/sr unknown
- 2010-10-15 PT PT10824148T patent/PT2488033T/pt unknown
- 2010-10-15 LT LTEP10824148.0T patent/LT2488033T/lt unknown
- 2010-10-15 EP EP22189749.9A patent/EP4159217B1/en active Active
- 2010-10-15 HU HUE10824148A patent/HUE046139T2/hu unknown
- 2010-10-15 NZ NZ598913A patent/NZ598913A/xx unknown
- 2010-10-15 PL PL19174594.2T patent/PL3560498T3/pl unknown
- 2010-10-15 EA EA201290149A patent/EA020589B1/ru not_active IP Right Cessation
-
2012
- 2012-03-27 CR CR20120155A patent/CR20120155A/es unknown
- 2012-04-03 DO DO2012000091A patent/DOP2012000091A/es unknown
- 2012-04-05 IL IL219073A patent/IL219073A/en active IP Right Grant
- 2012-04-11 ZA ZA2012/02612A patent/ZA201202612B/en unknown
- 2012-04-16 CL CL2012000964A patent/CL2012000964A1/es unknown
- 2012-04-27 CO CO12069732A patent/CO6531498A2/es active IP Right Grant
- 2012-05-11 MA MA34863A patent/MA33746B1/fr unknown
-
2014
- 2014-03-05 US US14/197,421 patent/US8952018B2/en active Active
- 2014-12-22 US US14/578,804 patent/US20150111904A1/en not_active Abandoned
-
2019
- 2019-09-06 HR HRP20191617 patent/HRP20191617T1/hr unknown
- 2019-09-09 CY CY20191100943T patent/CY1122013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6531498A2 (es) | COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS | |
| DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| PH12015502415A1 (en) | Combinations | |
| CL2012000917A1 (es) | Compuestos derivados de pirazolo [3,4-d] pirimidina, inhibidores btk; y uso en el tratamiento del cancer, enfermedades autoinmune, mastocitosis,osteoporosis,entre otras. | |
| CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. | |
| BRPI0807717A2 (pt) | Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas. | |
| PE20151070A1 (es) | Inhibidores de la tirosina - quinasa de bruton | |
| ECSP17038150A (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2011000409A1 (es) | Compuestos derivados de tieno[2,3-d]pirimidina; inhibidores de quinasa mnk1 y mnk2; composicion farmaceutica que los comprende y uso en el tratamiento de enfermedades metabolicas, hematopoyeticos, neurodegenerativas, renales, inflamatorias y cancer. | |
| CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
| CL2012000755A1 (es) | Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer. | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| BRPI0818366A2 (pt) | Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto. | |
| UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
| CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
| ECSP11011136A (es) | Compuestos útiles para inhibir chk1 | |
| CU20120002A7 (es) | DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA | |
| BR112016011222A2 (pt) | Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer | |
| EA201270537A1 (ru) | Комбинация | |
| ECSP11010959A (es) | Inhibidores de la integrasa del vih | |
| BR112015009134A2 (pt) | combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |